Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M41,200Revenue $M2,105Net Margin (%)12.7Z-Score22.9
Enterprise Value $M40,722EPS $3.8Operating Margin %30.6F-Score4
P/E(ttm))132Cash Flow Per Share $-2.0Pre-tax Margin (%)28.6Higher ROA y-yN
Price/Book16.210-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales17.05-y EBITDA Growth Rate %0Current Ratio5.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %22.0ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)15.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M101ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 405.2521%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 405.2521%New holding, 583 sh.583
REGNAndreas Halvorsen 2014-09-30 Reduce-2.35%$296.41 - $364.41
($335.27)
$ 405.2521%Reduce -63.53%1,080,682
REGNRay Dalio 2014-09-30 Reduce-0.04%$296.41 - $364.41
($335.27)
$ 405.2521%Reduce -91.3%1,600
REGNAndreas Halvorsen 2014-06-30 Add2.39%$277.29 - $313.74
($296.6)
$ 405.2537%Add 181.75%2,963,456
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 405.2537%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 405.2537%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 405.2537%New holding, 18400 sh.18,400
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 405.2537%New holding, 2295 sh.2,295
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 405.2537%New holding, 881 sh.881
REGNAndreas Halvorsen 2014-03-31 Buy 1.3%$267.62 - $347.62
($307.2)
$ 405.2532%New holding, 1051800 sh.1,051,800
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 405.2532%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 405.2532%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 405.2532%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 405.2541%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 405.2554%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 405.2554%New holding, 3285 sh.3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 405.2554%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 405.2574%Add 81.03%3,138,793
REGNRay Dalio 2013-06-30 Buy 0.01%$178.51 - $282.8
($232.86)
$ 405.2574%New holding, 4100 sh.4,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Ken Fisher 2014-09-3058300New Buy
REGN Joel Greenblatt 2014-09-301,41000.01+60.05%
REGN Frank Sands 2014-09-304,967,4664.914.4+1.22%
REGN Ron Baron 2014-09-307,1090.010.01
REGN Vanguard Health Care Fund 2014-09-302,795,5002.772.6
REGN Mario Gabelli 2014-09-302,19000-4.58%
REGN Andreas Halvorsen 2014-09-301,080,6821.071.6-63.53%
REGN Ray Dalio 2014-09-301,60000-91.3%
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Terifay Robert JSVP Commercial 2014-11-18Sell22,362$405.79-0.13view
Van Plew Daniel PSVP & General Mgr Industrial O 2014-11-13Sell8,575$399.341.48view
SCHLEIFER LEONARD SPresident & CEO 2014-11-12Sell45,817$400.31.24view
GOLDSTEIN JOSEPH LDirector 2014-11-12Sell5,000$398.311.74view
SCHLEIFER LEONARD SPresident & CEO 2014-10-31Sell3,453$400.111.28view
SCHLEIFER LEONARD SPresident & CEO 2014-10-28Sell69,112$404.010.31view
GOLDBERG MURRAY ASVP Administration & Asst Secr 2014-10-24Sell26,788$400.71.14view
BROWN MICHAEL SDirector 2014-10-24Sell5,000$3991.57view
Sanofi10% Owner 2014-10-16Buy122,127$335.3520.84view
Sanofi10% Owner 2014-10-15Buy158,368$328.1623.49view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 
    comment on REGN Mar 06 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
    Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
    52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 

    More From Our Partners
    Amgen Claims It All Nov 21 2014 - SEEKINGALPHA

    More From Other Websites
    REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 21 2014
    UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts Nov 21 2014
    Fighting kids' cancer, one voucher at a time Nov 21 2014
    New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
    Sanofi touts new drugs but diabetes outlook disappoints Nov 20 2014
    Regeneron & Sanofi Present Positive Data on PCSK9 Drug Nov 20 2014
    Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
    Regeneron Shares Could Reach $450 Nov 20 2014
    Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
    Sanofi eyes more than $38 bln from new drugs after CEO exit Nov 20 2014
    The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Nov 20 2014
    Sanofi, Regeneron eczema drug gets FDA fast-track designation Nov 20 2014
    Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
    Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
    The Forbes Healthcare Summit 2014: The Agenda Nov 19 2014
    Regeneron/Bayer's Eylea Gets Japanese Approval for DME Nov 19 2014
    3 Drugs Stocks Driving The Industry Higher Nov 19 2014
    Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab... Nov 19 2014
    Stocks Boosted by Merck's Vytorin Data Nov 19 2014
    Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK